About
My name is Eileen Handberg, PhD, ARNP, and I am a professor of medicine and director of the Cardiovascular Clinical Trials Program in the University of Florida Division of Cardiovascular Medicine. I serve the university as an Institutional Review Board alternate member, serve on the Promotion and Tenure Committee and am program co-director for the One Florida PCOR.net Clinical Data Research Network. I am an adult nurse practitioner providing cardiovascular care to patients for 30+ years. I fell in love with cardiology when I worked in the intensive care unit as a young nurse. I have practiced in almost every area of cardiology over the course of my career but have focused on ischemic heart disease, particularly in women, with specific interest in exercise intervention and other risk reduction strategies. My priority as a provider is to be there for my patients and for them to know it’s not just about the therapy I can prescribe. It’s about compassion and the ability to listen and assist them and their families with navigating the health care environment. I have spent the last 30 years running the Cardiovascular Clinical Trials Program at UF. Our mission has been to facilitate the research of faculty and fellows to improve our understanding of cardiovascular disease. I have participated in over 1,000 clinical trials during my career, many of which have resulted in the evidence that guides cardiology practice today. I have been an investigator and PI on many clinical trials over the years that have resulted in changes in treatment guidelines. I have been a WISE investigator, looking at women with nonobstructive coronary artery disease, and our research has led to a much better understanding of women with chest pain. I am program director for the practitioner competency assessment program, Florida CARES, one of only seven assessment centers in the U.S. I have been active in several professional societies, including the American Heart Association, American College of Cardiology and the Preventive Cardiovascular Nurses Association as its current president. My goal has been to make an impact in cardiovascular care, and being a part of these strong organizations has allowed me to do that. When I’m not practicing medicine, I enjoy working out and being on the water, especially at the beach. Dr. Handberg is a Research Professor of Medicine and Director of the Cardiovascular Clinical Trials Program in the Division of Cardiovascular Medicine. She also serves the University as an Institutional Review Board member, and representative on the College of Medicine Continuing Medical Education committee. She is an Adult Nurse Practitioner and has an outpatient practice, and manages research patient care. She is program Director for the practitioner competency assessment program Florida CARES, one of only 7 Assessment Centers in the US. An active member and current Trustee of the American College of Cardiology, Dr. Handberg serves on several committees including the ACC Scientific Sessions planning committee, PC3, Compensation, Metabolic Work Group, and is a member of the CV Team Council leadership group. She is the co-director of the ACC Core Curriculum for the Cardiovascular Clinician program, and served as co-chair of the Team-Based Work Group. She has served on several Presidential appointed committees including the search committee for the JACC Editor, and CEO search committee. She was the past Chair of the Nurse Education Committee, and has served on the Accreditation, BPQI committees and Anticoagulation Task Force. In 2009 she qualified for the designation FACC and was the first nurse (CCA) to achieve this recognition. Additionally she is a member of the American Heart Association’s Council on Cardiovascular Nursing and the Preventive Cardiovascular Nurses Association (PCNA), and is program director for the Vascular Biology Working Group (VBWG). She has contributed to over 90 articles, featured in the Journal of the American College of Cardiology, JAMA, Circulation, and the Journal of Women’s Health, among others.
View More >>Skills
Experience
Publication
-
July, 2021
Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial
Background Approximately half of all women with anginal symptoms and/or signs of ischemia and no obstructive coronary artery disease (INOCA) referred for coronary angiography have elevated ...
-
August, 2018
Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?
An increasing number of stable patients with evidence of ischemia but no obstructive coronary artery disease (CAD) at coronary angiography, now termed INOCA, are seen. Objective myocardial i...
-
December, 2017
Ten-Year Mortality in the WISE Study (Women’s Ischemia Syndrome Evaluation)
Background— The WISE study (Women’s Ischemia Syndrome Evaluation) was a prospective cohort study of 936 clinically stable symptomatic women who underwent coronary angiography to evaluat...
-
November, 2015
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and my...
Aims The mechanistic basis of the symptoms and signs of myocardial ischaemia in patients without obstructive coronary artery disease (CAD) and evidence of coronary microvascular dysfunction...
-
March, 2015
Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction: A National Heart, Lung, and...
Background— Women with signs and symptoms of ischemia and no obstructive coronary artery disease often have coronary microvascular dysfunction (CMD), diagnosed by invasive coronary reacti...
-
September, 2013
Anginal Symptoms, Coronary Artery Disease, and Adverse Outcomes in Black and White Women: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WI...
Background: Black women are less likely to be evaluated and treated for anginal symptoms, despite a higher premature cardiac mortality rate compared to white women. Our objective was to comp...
-
February, 2012
Relationships Between Cardiovascular Disease Risk Factors and Depressive Symptoms as Predictors of Cardiovascular Disease Events in Women
Background: Modifiable risk factors for cardiovascular disease (CVD) account for much of the variability in CVD outcomes and are also related to psychosocial variables. There is evidence tha...
-
January, 2012
Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease: Results From the NHLBI-Sponsored WISE (Women's Ischemia Sy...
Objectives: This study evaluated the safety of coronary reactivity testing (CRT) in symptomatic women with evidence of myocardial ischemia and no obstructive coronary artery disease (CAD). ...
-
October, 2011
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition ...
Background We investigated the role of the renin-angiotensin system in women with signs and symptoms of ischemia without obstructive coronary artery disease (CAD). Although microvascular dy...
-
August, 2011
Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary ...
Background: Microvascular coronary dysfunction (MCD) is associated with symptoms and signs of ischemia, and also adverse outcomes in women without macrovascular obstructive coronary artery ...
Scholar9 Profile ID
S9-012025-1708445

Publication
(23)

Article Reviewed
(0)

Citations
(3910)

Network
(14)

Conferences/Seminar
(0)